Microneedle Flu Vaccine Market – By Product Type (Solid, Hollow, Coated, Dissolving Microneedle), Vaccine Type (Trivalent, Quadrivalent), Flu Type (Influenza A [H1N1, H3N1], Influenza B), Global Forecast (2024 – 2032)

Microneedle Flu Vaccine Market Size

Microneedle Flu Vaccine Market size was valued at USD 1.6 billion in 2023 and is anticipated to witness growth at a CAGR of 6.1% from 2024 and 2032. High growth can be attributed to the increasing prevalence of influenza and the need for more efficient and effective vaccination methods, that has spurred the market demand.
 

Additionally, the ability of microneedles to enhance vaccine immunogenicity and reduce the risk of needle-stick injuries among healthcare workers further boosts their adoption. Moreover, advancements in microneedle technology have improved the stability and efficacy of vaccines, further driving market growth. Further, the convenience of self-administration and reduced dependency on healthcare professionals make microneedle vaccines particularly attractive in both developed and developing regions, thereby propelling market expansion.
 

Microneedle flu vaccines are a novel delivery method for influenza vaccines that use microscopic needles to deliver the vaccine into the skin. These needles are typically less than a millimeter in length and are designed to painlessly penetrate the outer layers of the skin, where they dissolve and release the vaccine.
 

Microneedle Flu Vaccine Market Trends

• Increasing prevalence of influenza and other viral infections is a significant growth driver for the market.
   
• For instance, as per the WHO, globally, there are around a billion cases of seasonal influenza annually, leading to 3–5 million cases of severe illness and 290,000 to 650,000 respiratory deaths annually.
   
• Similarly, as per the CDC estimates, there have been at least 35 million illnesses, 390,000 hospitalizations, and 24,000 deaths from flu in the U.S. till May 2024.
   
• Thus, as these infections continue to pose a global health threat, there is a growing emphasis on the development of effective and convenient vaccination methods, thereby fueling market growth.
   
• Further, microneedle-based vaccines offer several advantages over traditional needle-based vaccines, including improved patient compliance, reduced risk of needle-related injuries, and simplified vaccine administration, especially in mass vaccination campaigns.
   
• These factors are driving the adoption of microneedle flu vaccines, particularly in regions with high incidences of influenza and viral infections, thereby fueling the growth of the market.
   

Microneedle Flu Vaccine Market Analysis

Based on product type, the market is segmented into hollow microneedle, solid microneedle, coated microneedle, and dissolving microneedle. The hollow microneedle segment dominated the market in 2023 and accounted for USD 648.2 million.
 

• Hollow microneedles offer precise and controlled delivery of the vaccine directly into the dermis, which enhances immunogenicity and reduces the risk of needle-related injuries and infections.
   
• This method also minimizes patient discomfort, thereby improving compliance, especially among needle-phobic populations.
   
• Additionally, the scalability of hollow microneedle technology allows for cost-effective mass production, making it an attractive option for large-scale immunization programs.
   
• Moreover, growing preference for minimally invasive delivery systems and the increasing adoption of advanced drug delivery technologies further bolster the market position of hollow microneedles in the flu vaccine sector.
   

Based on vaccine type, the microneedle flu vaccine market is segmented into trivalent flu vaccine and quadrivalent flu vaccine. The quadrivalent flu vaccine segment dominated the market with 68% of market share in 2023.
 

• The quadrivalent flu vaccine segment commands a significant share in the market, driven by its ability to offer broader protection against influenza.
   
• Quadrivalent vaccines include two strains each of influenza A and B viruses, thereby enhancing their efficacy compared to trivalent vaccines, which cover only three strains.
   
• This inclusion of an additional B strain in quadrivalent vaccines provides enhanced protection, making them preferable in a market increasingly focused on comprehensive flu prevention.
   

Based on flu type, the microneedle flu vaccine market is segmented into influenza A and influenza B. The influenza A segment is further divided into H1N1 and H3N1. The influenza A segment held highest market share in 2023 and is anticipated to grow at a CAGR of 5.7% over the forecast years.
 

• Influenza A viruses are a significant cause of respiratory illnesses, with children being efficient transmitters of the virus. The global attack rate of influenza is estimated at 5-10% in adults and 20-30% in children annually.
   
• For instance, in the U.S., during the 2021-2022 season, the rate of influenza A(H3N2) virus infection among household contacts of patients diagnosed with influenza was 50.0%, significantly higher than in prior seasons.
   
• Additionally, influenza A is known for its high mutation rate and potential to cause pandemics, making it a significant public health concern. This has led to substantial investments in research and development of effective vaccines.
   

North America microneedle flu vaccine market was valued at USD 964.4 million in 2023 and is anticipated to reach USD 1.6 billion by 2032.
 

• The region's robust healthcare infrastructure and high adoption rates of advanced medical technologies play a significant role.
   
• Additionally, North America's proactive approach to vaccination campaigns, coupled with substantial government support and funding for innovative vaccine delivery systems, further drives market growth.
   
• Moreover, increasing awareness and acceptance of minimally invasive vaccination methods among the population enhance the market's penetration and adoption rates.
   

The U.S. microneedle flu vaccine market is anticipated to grow at a CAGR of 5.7% between 2024 - 2032.
 

• The U.S. holds a significant market share in the market, driven by advanced healthcare infrastructure, substantial investments in research and development, and a high adoption rate of innovative medical technologies.
   
• Furthermore, the presence of leading pharmaceutical companies and collaborations between academia and industry foster a robust environment for the development and commercialization of microneedle flu vaccines. This combination of factors positions the U.S. as a dominant player in the global market.
   

UK is anticipated to witness robust growth in the global microneedle flu vaccine market.
 

• The country's strong focus on advancing healthcare technologies and its robust investment in research and development play a critical role.
   
• Additionally, the presence of leading pharmaceutical companies and research institutions in the UK has facilitated the development and commercialization of microneedle flu vaccines.
   
• These efforts are further bolstered by strategic partnerships and collaborations between academic institutions, healthcare providers, and biotech firms.
   

China microneedle flu vaccine market is anticipated to witness lucrative growth between 2024 – 2032.
 

• High prevalence of influenza cases in the country drives the market growth. For instance, in 2021, over 668,200 influenza cases were reported in China, accounting for 10.72% of total infectious disease cases.
   
• Additionally, the country's large population, increasing healthcare infrastructure, and growing awareness about the benefits of vaccination are driving the demand for innovative and more patient-friendly vaccination methods.
   
• Additionally, the Chinese government's initiatives to expand access to healthcare and prevent infectious diseases further support the growth of the market in the country.
   

Microneedle Flu Vaccine Market Share

The competitive landscape of the microneedle flu vaccine industry is characterized by the presence of several key players striving to gain a significant market share. These companies are focusing on strategic partnerships, collaborations, and acquisitions to enhance their product portfolios and expand their market presence. Additionally, the market is witnessing the entry of new players, which is intensifying the competition. With the growing demand for painless and convenient vaccination methods, the market is expected to witness further competition and innovation in the coming years.
 

Microneedle Flu Vaccine Market Companies

Prominent players operating in the microneedle flu vaccine industry include:

• 3M
• Becton, Dickinson and Company
• Corium International, Inc.
• CosMED Pharmaceuticals Co., Ltd
• FluGen, Inc
• Sanofi
   

Microneedle Flu Vaccine Industry News:

• In October 2023, 3M Company received FDA authorization for VaxiPatch, a microneedle patch for influenza vaccine. This helped the company increase sales of its product in the U.S.
   
• In September 2023, Vaxess Technologies announced that it raised an additional USD 9 million in venture capital funding to support its vaccine delivery technology. This helped the company in accelerating the development of its mRNA vaccine patch technology.
   
• In April 2022, Vaxess Technologies, Inc., announced the production of the first GMP batch of MIMIX Technology Vaccine Patches for an upcoming Phase I seasonal influenza clinical trial.
   

The microneedle flu vaccine market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 - 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Hollow microneedle
• Solid microneedle
• Coated microneedle
• Dissolving microneedle

Market, By Vaccine Type

• Trivalent flu vaccine
• Quadrivalent flu vaccine

Market, By Flu Type

• Influenza A
  • H1N1
  • H3N1
• Influenza B

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa